Sher Karki

6.6k total citations · 1 hit paper
38 papers, 4.4k citations indexed

About

Sher Karki is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Cell Biology. According to data from OpenAlex, Sher Karki has authored 38 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Radiology, Nuclear Medicine and Imaging, 20 papers in Molecular Biology and 14 papers in Cell Biology. Recurrent topics in Sher Karki's work include Monoclonal and Polyclonal Antibodies Research (21 papers), Microtubule and mitosis dynamics (12 papers) and Cellular transport and secretion (10 papers). Sher Karki is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (21 papers), Microtubule and mitosis dynamics (12 papers) and Cellular transport and secretion (10 papers). Sher Karki collaborates with scholars based in United States, Germany and Canada. Sher Karki's co-authors include Erika L.F. Holzbaur, Greg A. Lazar, John R. Desjarlais, Mariko Tokito, Clare M. Waterman, Hsing Chen, Elizabeth A Holleran, Wei Dang, Holly M. Horton and Gregory L. Moore and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Sher Karki

38 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Engineered antibody Fc variants with enhanced effector function

2006 590 citations Greg A. Lazar, Wei Dang et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Sher Karki

Since Specialization

Citations

This map shows the geographic impact of Sher Karki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sher Karki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sher Karki more than expected).

Fields of papers citing papers by Sher Karki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sher Karki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sher Karki. The network helps show where Sher Karki may publish in the future.

Co-authorship network of co-authors of Sher Karki

This figure shows the co-authorship network connecting the top 25 collaborators of Sher Karki. A scholar is included among the top collaborators of Sher Karki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sher Karki. Sher Karki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1372 XmAb143, an engineered IL18 heterodimeric Fc-fusion, features improved stability, reduced potency, and insensitivity to IL18BP 2022 ·Regular and Young Investigator Award Abstracts ·Alex Nisthal, Sung‐Hyung Lee, Christine Bonzon, Ruschelle Love, Kendra N. Avery, Rumana Rashid, Panida Lertkiatmongkol, (unknown), Sher Karki, Norman J. Barlow, Seung Y. Chu, Gregory Moore, John R. Desjarlais	3
2	Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia 2017 ·Molecular Cancer Therapeutics ·Hui Zhao, (unknown), Sathish Kumar Ganesan, (unknown), Karen Morrison, Zhilan Zeng, Verónica Robles, Josh Snyder, (unknown), Héctor Aviña, Sher Karki, David R. Stover, Fernando Doñate	47
3	Abstract 2709: Evaluation of CD37 expression and binding of AGS67E, an antibody-drug conjugate (ADC) against CD37, on white blood cells (WBCs) collected from phase I non-Hodgkin lymphoma (NHL) patients 2017 ·Cancer Research ·Sher Karki, Héctor Aviña, (unknown), Ahmed Sawas, Kerry J. Savage, Raymond P. Perez, Ranjana H. Advani, Jasmine Zain, Owen A. O’Connor, (unknown), Hui Zhao, (unknown), Karen Morrison, Leonard Reyno, Fernando Doñate	1
4	APP Regulates Microglial Phenotype in a Mouse Model of Alzheimer's Disease 2016 ·Journal of Neuroscience ·Gunjan D. Manocha, Angela M. Floden, (unknown), Joshua A. Kulas, (unknown), Lalida Rojanathammanee, (unknown), Kendra L. Puig, Sher Karki, Michael R. Nichols, Diane C. Darland, James E. Porter, Colin K. Combs	45
5	A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens 2011 ·mAbs ·Gregory L. Moore, (unknown), Erik Pong, Duc-Hanh T. Nguyen, Jonathan Jacinto, Araz Eivazi, Umesh S. Muchhal, Sher Karki, Seung Y. Chu, Greg A. Lazar	89
6	Enhanced antibody half-life improves in vivo activity 2010 ·Nature Biotechnology ·Jonathan Zalevsky, Aaron K. Chamberlain, Holly M. Horton, Sher Karki, Irene Leung, Thomas J. Sproule, Greg A. Lazar, Derry C. Roopenian, John R. Desjarlais	449
7	Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions 2010 ·mAbs ·Gregory L. Moore, Hsing Chen, Sher Karki, Greg A. Lazar	193
8	Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia 2008 ·Cancer Research ·Holly M. Horton, Matthew J. Bernett, Erik Pong, Matthias Peipp, Sher Karki, Seung Y. Chu, John O. Richards, Igor Voštiar, Patrick F. Joyce, Roland Repp, John R. Desjarlais, Eugene A. Zhukovsky	187
9	Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells 2008 ·Molecular Cancer Therapeutics ·John O. Richards, Sher Karki, Greg A. Lazar, Hsing Chen, Wei Dang, John R. Desjarlais	235
10	Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies 2008 ·Molecular Immunology ·Seung Y. Chu, Igor Voštiar, Sher Karki, Gregory L. Moore, Greg A. Lazar, Erik Pong, Patrick F. Joyce, David E. Szymkowski, John R. Desjarlais	119
11	Engineered antibody Fc variants with enhanced effector function breakdown → 2006 ·Proceedings of the National Academy of Sciences ·Greg A. Lazar, Wei Dang, Sher Karki, Omid Vafa, (unknown), (unknown), Cheryl Chan, Helen Chung, Araz Eivazi, Sean C. Yoder, Jost Vielmetter, David F. Carmichael, Robert J. Hayes, Bassil I. Dahiyat	590
12	A molecular immunology approach to antibody humanization and functional optimization 2006 ·Molecular Immunology ·Greg A. Lazar, John R. Desjarlais, Jonathan Jacinto, Sher Karki, Philip W. Hammond	78
13	PLAC-24 Is a Cytoplasmic Dynein-Binding Protein That Is Recruited to Sites of Cell-Cell Contact 2002 ·Molecular Biology of the Cell ·Sher Karki, Lee A. Ligon, (unknown), Mariko Tokito, Erika L.F. Holzbaur	19
14	Dynein binds to β-catenin and may tether microtubules at adherens junctions 2001 ·Nature Cell Biology ·Lee A. Ligon, Sher Karki, Mariko Tokito, Erika L.F. Holzbaur	230
15	A Dynactin Subunit with a Highly Conserved Cysteine-rich Motif Interacts Directly with Arp1 2000 ·Journal of Biological Chemistry ·Sher Karki, Mariko Tokito, Erika L.F. Holzbaur	32
16	Cytoplasmic dynein and dynactin in cell division and intracellular transport 1999 ·Current Opinion in Cell Biology ·Sher Karki, Erika L.F. Holzbaur	385
17	The Role of the Dynactin Complex in Intracellular Motility 1998 ·International review of cytology ·Elizabeth A Holleran, Sher Karki, Erika L.F. Holzbaur	124
18	The Involvement of the Intermediate Chain of Cytoplasmic Dynein in Binding the Motor Complex to Membranous Organelles ofXenopusOocytes 1997 ·Molecular Biology of the Cell ·Steffen Walter, Sher Karki, Kevin T. Vaughan, Richard B. Vallee, Erika L.F. Holzbaur, Dieter G. Weiss, С. А. Кузнецов	99
19	Casein Kinase II Binds to and Phosphorylates Cytoplasmic Dynein 1997 ·Journal of Biological Chemistry ·Sher Karki, Mariko Tokito, (unknown)	57
20	Affinity Chromatography Demonstrates a Direct Binding between Cytoplasmic Dynein and the Dynactin Complex 1995 ·Journal of Biological Chemistry ·Sher Karki, Erika L.F. Holzbaur	285

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact